Insider Trading Alert - REGN, HK, IFF, IDXX And WLL Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 6, 2013, 120 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $600.78 to $11,115,720.00.

Highlighted Stocks Traded by Insiders:

Regeneron Pharmaceuticals (REGN) - FREE Research Report

Goldstein Joseph L who is Director at Regeneron Pharmaceuticals sold 1,000 shares at $300.74 on Nov. 6, 2013. Following this transaction, the Director owned 3,000 shares meaning that the stake was reduced by 25% with the 1,000 share transaction.

The shares most recently traded at $271.45, down $29.29, or 10.79% since the insider transaction. Historical insider transactions for Regeneron Pharmaceuticals go as follows:

  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 11,500

The average volume for Regeneron Pharmaceuticals has been 711,300 shares per day over the past 30 days. Regeneron Pharmaceuticals has a market cap of $29.2 billion and is part of the health care sector and drugs industry. Shares are up 76.72% year to date as of the close of trading on Wednesday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 42.3. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGN - FREE

TheStreet Quant Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Halcon Resources (HK) - FREE Research Report

Obut Tina S who is VP, Corporate Reserves at Halcon Resources bought 5,000 shares at $4.67 on Nov. 6, 2013. Following this transaction, the VP, Corporate Reserves owned 179,010 shares meaning that the stake was reduced by 2.87% with the 5,000 share transaction.

Cusack Charles E III who is EVP, Chief Operating Officer at Halcon Resources bought 20,000 shares at $4.75 on Nov. 6, 2013. Following this transaction, the EVP, Chief Operating Officer owned 432,240 shares meaning that the stake was reduced by 4.85% with the 20,000 share transaction.

The shares most recently traded at $4.53, down $0.22, or 4.86% since the insider transaction. Historical insider transactions for Halcon Resources go as follows:

  • 12-Week # shares bought: 70,000
  • 24-Week # shares bought: 5.9 million

The average volume for Halcon Resources has been 6.0 million shares per day over the past 30 days. Halcon Resources has a market cap of $2.1 billion and is part of the basic materials sector and energy industry. Shares are down 26.16% year to date as of the close of trading on Wednesday.

Halcon Resources Corporation, an independent energy company, engages in the acquisition, production, exploration, and development of onshore oil and natural gas properties in the United States. Currently there are 7 analysts that rate Halcon Resources a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HK - FREE

TheStreet Quant Ratings rates Halcon Resources as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Halcon Resources Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

International Flavors & Fragrances (IFF) - FREE Research Report

Mirzayantz Nicolas who is Group President Fragrance at International Flavors & Fragrances sold 3,000 shares at $85.00 on Nov. 6, 2013. Following this transaction, the Group President Fragrance owned 70,439 shares meaning that the stake was reduced by 4.09% with the 3,000 share transaction.

The shares most recently traded at $85.88, up $0.88, or 1.02% since the insider transaction. Historical insider transactions for International Flavors & Fragrances go as follows:

  • 12-Week # shares sold: 5,460
  • 24-Week # shares sold: 18,094

The average volume for International Flavors & Fragrances has been 262,800 shares per day over the past 30 days. International Flavors & Fragrances has a market cap of $6.9 billion and is part of the basic materials sector and chemicals industry. Shares are up 26.57% year to date as of the close of trading on Wednesday.

International Flavors & Fragrances Inc., together with its subsidiaries, creates, manufactures, and supplies flavor and fragrance products worldwide. The company operates in two segments, Flavors and Fragrances. The stock currently has a dividend yield of 1.85%. The company has a P/E ratio of 19.3. Currently there are 6 analysts that rate International Flavors & Fragrances a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IFF - FREE

TheStreet Quant Ratings rates International Flavors & Fragrances as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full International Flavors & Fragrances Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Idexx Laboratories (IDXX) - FREE Research Report

Szostak M Anne who is Director at Idexx Laboratories bought 1,000 shares at $108.24 on Nov. 6, 2013. Following this transaction, the Director owned 3,000 shares meaning that the stake was reduced by 50% with the 1,000 share transaction.

The shares most recently traded at $108.91, up $0.67, or 0.62% since the insider transaction. Historical insider transactions for Idexx Laboratories go as follows:

  • 4-Week # shares sold: 2,500
  • 12-Week # shares sold: 3,513
  • 24-Week # shares sold: 3,513

The average volume for Idexx Laboratories has been 257,300 shares per day over the past 30 days. Idexx Laboratories has a market cap of $5.6 billion and is part of the health care sector and drugs industry. Shares are up 17.11% year to date as of the close of trading on Wednesday.

IDEXX Laboratories, Inc. develops, manufactures, and distributes various products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. The company has a P/E ratio of 31.7. Currently there are 5 analysts that rate Idexx Laboratories a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IDXX - FREE

TheStreet Quant Ratings rates Idexx Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Idexx Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Whiting Petroleum Corporation (WLL) - FREE Research Report

Brown James T who is President and COO at Whiting Petroleum Corporation sold 10,900 shares at $66.99 on Nov. 6, 2013. Following this transaction, the President and COO owned 101,788 shares meaning that the stake was reduced by 9.67% with the 10,900 share transaction.

Jensen Brent P who is Treasurer at Whiting Petroleum Corporation sold 1,598 shares at $67.47 on Nov. 6, 2013. Following this transaction, the Treasurer owned 30,250 shares meaning that the stake was reduced by 5.02% with the 1,598 share transaction.

Ross Rick A Mr. who is Vice President at Whiting Petroleum Corporation sold 10,000 shares at $67.14 on Nov. 6, 2013. Following this transaction, the Vice President owned 23,590 shares meaning that the stake was reduced by 29.77% with the 10,000 share transaction.

The shares most recently traded at $61.71, down $5.43, or 8.8% since the insider transaction. Historical insider transactions for Whiting Petroleum Corporation go as follows:

  • 4-Week # shares sold: 70,908
  • 12-Week # shares sold: 70,908
  • 24-Week # shares sold: 70,908

The average volume for Whiting Petroleum Corporation has been 2.1 million shares per day over the past 30 days. Whiting Petroleum Corporation has a market cap of $7.9 billion and is part of the basic materials sector and energy industry. Shares are up 54.02% year to date as of the close of trading on Wednesday.

Whiting Petroleum Corporation, an independent oil and gas company, engages in the acquisition, exploration, exploitation, development, and production of crude oil, natural gas liquids, and natural gas in the United States. The company has a P/E ratio of 15.7. Currently there are 19 analysts that rate Whiting Petroleum Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WLL - FREE

TheStreet Quant Ratings rates Whiting Petroleum Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, expanding profit margins, good cash flow from operations and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Whiting Petroleum Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

What Angela Merkel's Uncertain Political Future Means for Greece's Debt Woes

What Angela Merkel's Uncertain Political Future Means for Greece's Debt Woes

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern